Evidence map›Paper›PMID 37818664›Full record

ArticleInternational journal of technology assessment in health care2023

Proposing a health-specific organizational impact framework to evaluate organizational impacts in health technology assessments.

Caryn Mathy, Christophe Pascal, Isabelle Bongiovanni-Delarozière, Lauriane Favez

Abstract read
In one paragraph

Article in International journal of technology assessment in health care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Organizational impact in healthcare in France: a decade of insights but chicken and egg situation.International journal of technology assessment in health care · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Caryn MathySchool of Engineering and Management Vaud, HES-SO University of Applied Sciences and Arts Western Switzerland, Yverdon-les-Bains, Switzerland.ORCID https://orcid.org/0000-0002-4500-4588
Christophe PascalUniv Lyon, Jean Moulin, IFROSS, CRDMS, Lyon, France.ORCID https://orcid.org/0000-0002-4667-644X
Isabelle Bongiovanni-DelarozièreHaute Autoritè de Santè, Medical and Public Health Evaluation Division, Saint-Denis la Plaine, France.
Lauriane FavezSchool of Engineering and Management Vaud, HES-SO University of Applied Sciences and Arts Western Switzerland, Yverdon-les-Bains, Switzerland.ORCID https://orcid.org/0000-0002-3690-4939

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesHealth technology assessments (HTAs) have traditionally included clinical and cost-effectiveness evaluation of new health technologies (HTs). However, new HTs can generate important organizational impacts (OIs) that influence their overall value. OIs are currently not clearly identified and evaluated in HTA procedures and tools are limited. To address this issue, a comprehensive framework that allows to assess OIs of new HTs in HTAs is proposed.

methodsA working and methodological group identified the Oslo Manual 2018, 4th edition, OECD/Eurostat, on the objectives and outcomes of commercial innovations as the basis for the OIs framework for HTAs. The Oslo Manual was translated to the healthcare sector and adapted to HTA procedures through a three-step process.

resultsThe framework is composed of three main parts. Part I tackles the context of the evaluation, Part II the categories of impacts and the specific impacts - in total, 16 OIs were identified - and Part III the stakeholders involved. The central part of the framework is Part II, and consists of three categories of impacts: (i) on the care process, (ii) on the stakeholders' capabilities and skills, and (iii) on society or the community.

conclusionsThis framework provides a comprehensive and structured basis to document OIs of new HTs. It thus contributes to the extension of HTA evaluation criteria to other dimensions than clinical and economic aspects, that is, organizational aspects. Some of its intrinsic limitations and the questions they raise in the field for policy-makers, practitioners, and researchers are discussed.

Indexed as

Cost-Effectiveness AnalysisTechnology Assessment, Biomedicalbiomedical technologydecision makingequipment and supplieshealth impact assessmentorganization and administrationtechnology assessment biomedical

Identifiers

PMID37818664
PMCPMC11570118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.